Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy

Area of Science:

• Nephrology
• Immunology
• Clinical Trials

Background:

• Current guidelines recommend monitoring anti-phospholipase A2 receptor (PLA2R) antibody levels for treatment response in membranous nephropathy.
• Optimal timing for antibody level assessment and integration with clinical factors remain unclear.

Purpose of the Study:

• To identify optimal timing and predictors of treatment response in membranous nephropathy using anti-PLA2R antibody levels.
• To compare the predictive performance of models at different time points (baseline, 3 months, 6 months).

Main Methods:

• Analysis of 85 patients from the MENTOR trial treated with cyclosporine or rituximab.
• Development of logistic regression models using anti-PLA2R antibody levels, creatinine clearance, and albumin levels at baseline, 3 months, and 6 months.
• Evaluation of model performance using C-statistics and model fit (AIC, R²).

Main Results:

• A baseline model predicting no remission included high anti-PLA2R antibodies (>323 RU/ml) and creatinine clearance.
• A 3-month model incorporating changes in anti-PLA2R antibodies and albumin levels showed improved predictive performance (C-statistic 0.93, R² 51.8%).
• A 6-month model offered no significant improvement over the 3-month model.

Conclusions:

• Combining anti-PLA2R antibody levels with albumin levels at 3 months is the optimal strategy for predicting treatment response in membranous nephropathy.
• This 3-month assessment is superior to baseline evaluation and offers no added benefit when delayed to 6 months.
• Findings provide a refined approach to monitoring treatment efficacy in anti-PLA2R antibody-associated membranous nephropathy.